287 related articles for article (PubMed ID: 29042365)
1. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.
Nieborowska-Skorska M; Maifrede S; Dasgupta Y; Sullivan K; Flis S; Le BV; Solecka M; Belyaeva EA; Kubovcakova L; Nawrocki M; Kirschner M; Zhao H; Prchal JT; Piwocka K; Moliterno AR; Wasik M; Koschmieder S; Green TR; Skoda RC; Skorski T
Blood; 2017 Dec; 130(26):2848-2859. PubMed ID: 29042365
[TBL] [Abstract][Full Text] [Related]
2. Low
Makarik TV; Abdullaev AO; Nikulina EE; Treglazova SA; Stepanova EE; Subortseva IN; Kovrigina AM; Melikyan AL; Kulikov SM; Sudarikov AB
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33921387
[No Abstract] [Full Text] [Related]
3. MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.
Yasuda S; Aoyama S; Yoshimoto R; Li H; Watanabe D; Akiyama H; Yamamoto K; Fujiwara T; Najima Y; Doki N; Sakaida E; Edahiro Y; Imai M; Araki M; Komatsu N; Miura O; Kawamata N
Int J Hematol; 2021 Oct; 114(4):424-440. PubMed ID: 34165774
[TBL] [Abstract][Full Text] [Related]
4. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
Rabade N; Subramanian PG; Kodgule R; Raval G; Joshi S; Chaudhary S; Mascarenhas R; Tembhare P; Gujral S; Patkar N
Indian J Pathol Microbiol; 2018; 61(2):209-213. PubMed ID: 29676359
[TBL] [Abstract][Full Text] [Related]
5. Study of CALR, MPL, and c-kit Gene Mutations in Thai Patients with JAK2 V617F Negative Myeloproliferative Neoplasms.
Wiriyaukaradecha K; Nimsanor S; Tantirukdham N; Tongsom J; Bunyoo C; Soonklang K; Sritana N; Auewarakul C
Asian Pac J Cancer Prev; 2022 May; 23(5):1671-1678. PubMed ID: 35633552
[TBL] [Abstract][Full Text] [Related]
6. Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish.
Lim KH; Chang YC; Chiang YH; Lin HC; Chang CY; Lin CS; Huang L; Wang WT; Gon-Shen Chen C; Chou WC; Kuo YY
Blood Cancer J; 2016 Oct; 6(10):e481. PubMed ID: 27716741
[TBL] [Abstract][Full Text] [Related]
7. The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.
Lin Y; Liu E; Sun Q; Ma J; Li Q; Cao Z; Wang J; Jia Y; Zhang H; Song Z; Ai X; Shi L; Feng X; Li C; Wang J; Ru K
Am J Clin Pathol; 2015 Jul; 144(1):165-71. PubMed ID: 26071474
[TBL] [Abstract][Full Text] [Related]
8. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Labastida-Mercado N; Galindo-Becerra S; Garcés-Eisele J; Colunga-Pedraza P; Guzman-Olvera V; Reyes-Nuñez V; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):16-21. PubMed ID: 25637689
[TBL] [Abstract][Full Text] [Related]
9. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
10. Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.
Choong ML; Pecquet C; Pendharkar V; Diaconu CC; Yong JW; Tai SJ; Wang SF; Defour JP; Sangthongpitag K; Villeval JL; Vainchenker W; Constantinescu SN; Lee MA
J Cell Mol Med; 2013 Nov; 17(11):1397-409. PubMed ID: 24251790
[TBL] [Abstract][Full Text] [Related]
11. Correlation analysis between JAK2, MPL, and CALR mutations in patients with myeloproliferative neoplasms of Chinese Uygur and Han nationality and their clinical characteristics.
Lang T; Nie Y; Wang Z; Huang Q; An L; Wang Y; Wufuer G; Maimaiti A; Fu L; Li Y; Zhang X; Aisimutula A; Wang X; Zhu L; Liu H; Mao M
J Int Med Res; 2018 Nov; 46(11):4650-4659. PubMed ID: 30084272
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms.
Patel PR; Senyuk V; Rodriguez NS; Oh AL; Bonetti E; Mahmud D; Barosi G; Mahmud N; Rondelli D
Biol Blood Marrow Transplant; 2019 May; 25(5):855-860. PubMed ID: 30615982
[TBL] [Abstract][Full Text] [Related]
13. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
14. SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms.
Pandey G; Mazzacurati L; Rowsell TM; Horvat NP; Amin NE; Zhang G; Akuffo AA; Colin-Leitzinger CM; Haura EB; Kuykendall AT; Zhang L; Epling-Burnette PK; Reuther GW
Am J Hematol; 2024 Jun; 99(6):1040-1055. PubMed ID: 38440831
[TBL] [Abstract][Full Text] [Related]
15. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
16. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
17. Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms.
Pratz KW; Koh BD; Patel AG; Flatten KS; Poh W; Herman JG; Dilley R; Harrell MI; Smith BD; Karp JE; Swisher EM; McDevitt MA; Kaufmann SH
Clin Cancer Res; 2016 Aug; 22(15):3894-902. PubMed ID: 26979391
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous detection of JAK2, CALR, and MPL mutations and quantitation of JAK2 V617F allele burden in myeloproliferative neoplasms using the quenching probe-Tm method in i-densy IS-5320.
Arai K; Sakaguchi M; Yui S; Kitano T; Miyata M; Yogosawa M; Nakayama K; Tajika K; Usuki K; Kuroda J; Uoshima N; Kobayashi Y; Uchiyama H; Kubota Y; Kimura S; Mori S; Hirai M; Wakita S; Yamaguchi H
Int J Lab Hematol; 2022 Dec; 44(6):1102-1110. PubMed ID: 36039795
[TBL] [Abstract][Full Text] [Related]
19.
Maifrede S; Le BV; Nieborowska-Skorska M; Golovine K; Sullivan-Reed K; Dunuwille WMB; Nacson J; Hulse M; Keith K; Madzo J; Caruso LB; Gazze Z; Lian Z; Padella A; Chitrala KN; Bartholdy BA; Matlawska-Wasowska K; Di Marcantonio D; Simonetti G; Greiner G; Sykes SM; Valent P; Paietta EM; Tallman MS; Fernandez HF; Litzow MR; Minden MD; Huang J; Martinelli G; Vassiliou GS; Tempera I; Piwocka K; Johnson N; Challen GA; Skorski T
Cancer Res; 2021 Oct; 81(19):5089-5101. PubMed ID: 34215619
[TBL] [Abstract][Full Text] [Related]
20. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
